CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL

Blood

Volumn 111, Issue 7, 2008, Pages 3884-3892

  Matte Martone, Catherine ^a   Liu, Jinli ^b   Jain, Dhanpat ^c   McNiff, Jennifer ^c   Shlomchik, Warren D ^a,c  

^a YALE CANCER CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BLOOD GROUP H ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; LYMPHOCYTE ANTIGEN RECEPTOR; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CHIMERA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOLYSIS; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ALLOTRANSPLANTATION; ANIMAL; DISEASE MODEL; GENETICS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; STEM CELL TRANSPLANTATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, KNOCKOUT; MINOR HISTOCOMPATIBILITY ANTIGENS; RECEPTORS, ANTIGEN, T-CELL; STEM CELL TRANSPLANTATION; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 43549106639     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-125294     Document Type: Article

References (38)

1. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997;157:61-72.
2. Mackall CL, Hakim FT, Gress RE. Restoration of T-cell homeostasis after T-cell depletion. Semin Immunol. 1997;9:339-346.
3. Hakim FT, Memon SA, Gepeda R, et al. Age- dependent incidence, time course, and consequences of thymic renewal in adults. J Clin Invest. 2005;115:930-939.
4. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-vs-leukaemia effect. Nat Rev Cancer. 2004;4:371-380.
5. Teshima T, Ordemann R, Reddy P, et al. Acute graft-vs-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8: 575-581.
6. Aosai F, Ohlen C, Ljunggren HG, et al. Different types of allospecific CTL clones identified by their ability to recognize peptide loading-defective target cells. Eur J Immunol. 1991;21:2767-2774.
7. Man S, Salter RD, Engelhard VH. Role of endogenous peptide in human alloreactive cytotoxic T cell responses. Int Immunol. 1992;4:367-375.
8. Crumpacker DB, Alexander J, Cresswell P, Engelhard VH. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2. J Immunol. 1992;148:3004-3011.
9. Hambach L, Goulmy E. Immunotherapy of cancer through targeting of minor histocompatibility antigens. CurrOpin Immunol. 2005;17:202-210.
10. Hill GR, Krenger W, Ferrara JL. The role of cytokines in acute graft-vs-host disease. Cytokines Cell Mol Ther. 1997:3:257-266.
11. Korngold R, Sprent J. Features of T cells causing H-2-restricted lethal graft-vs.-host disease across minor histocompatibility barriers. J Exp Med. 1982;155:872-883.
12. Jones SC, Murphy GF Friedman TM, Korngold R. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-vs-host disease model. J Clin Invest. 2003;112:1880-1886.
13. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10:987-992.
14. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft vs host disease by inactivation of host antigen-presenting cells. Science. 1999; 285:412-415.
15. Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ, ShlomGhik WD. Target antigens determine graft-vs-host disease phenotype. J Immunol. 2004;173:5467-5475.
16. Morita S, Kojima T, Kitamura T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 2000;7:1063-1066.
17. Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998;92: 3780-3792.
18. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90:8392-8396.
19. Matte CC, Cormier J, Anderson BE, et al. Graft- vs-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood. 2004; 103:4353-4361.
20. Reddy UR, Venkatakrishnan G, Maul GG, Roy AK, Ross AH. Transient expression of full-length and truncated forms of the human nerve growth factor receptor. Brain Res Mol Brain Res. 1990;8: 137-141.
21. Issekutz TB, Stoltz JM, van der Meide P. Lymphocyte recruitment in delayed-type hypersensitivity: the role of IFN-gamma. J Immunol. 1988;140: 2989-2993.
22. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm [review]. Cell. 1994;76:301-314.
23. Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graft-vs-host reactive T cells to peripheral tissues. J Exp Med. 2006;203:2021-2031.
24. Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation. 2003;76:1503-1510.
25. Emerson SG, Cone RE. I-Kκ and H-2Kκ antigens are shed as supramolecular particles in association with membrane lipids. J Immunol. 1981 ;127: 482-486.
26. Emerson SG, Cone RE. Absorption of shed l-Aκ and H-2Kκ antigens by lymphoid cells. Transplantation. 1982;33:36-40.
27. Herrera OB, Golshayan D, Tibbott R, et al. A novel pathway of alloantigen presentation by dendritic cells. J Immunol. 2004;173:4828-4837.
28. van den Brink MR, Burakoff SJ. Cytolytic path-ways in haematopoietic stem-cell transplantation. Nat Rev Immunol. 2002;2:273-281.
29. Marks L, Altman NH, Podack ER, Levy RB. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation. 2004; 77:804-812.
30. Giorno R, Choi KL Katz HR, Claman HN. Monoclonal antibody analysis of skin in chronic murine graft vs host disease produced across minor histocompatibility barriers. Cell Immunol. 1987:106: 76-87.
31. Bland PW, Whiting CV. Induction of MHC class II gene products in rat intestinal epithelium during graft-vs-host disease and effects on the immune function of the epithelium. Immunology. 1992;75: 366-371.
32. Li S, Kurts C, Kontgen F, Holdsworth SR, Tipping PG. Major histocompatibility complex class II expression by intrinsic renal cells is required for crescentic glomerulonephritis. J Exp Med. 1998; 188:597-602.
33. Anderson BE. McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4 + Tcells that survive irradiation regulate chronic graft-vs-host disease. Blood. 2004;104:1565- 1573.
34. Anderson BE, McNiff JM, Jain D, Blazar BR, Shlomchik WD, Shlomchik MJ. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-vs-host disease: requirements depend on target organ. Blood. 2005;105:2227-2234.
35. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 1999;8:265-277.
36. Duffield JS, Forbes SJ, Constandinou CM, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest. 2005;115:56-65.
37. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-vs-leukemia responses. Nat Med. 2005;11: 1244-1249.
38. ShlomchikWD, Matte-Martone CC, Gilliland DG, Chen LP. Mechanisms of GVL against a murine blast crisis CML [abstract]. Blood. 2006;108:60a-61a.